Equillium, Inc. (EQ): Price and Financial Metrics

Equillium, Inc. (EQ): $0.64

0.01 (+0.83%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add EQ to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#304 of 476

in industry

EQ Price/Volume Stats

Current price $0.64 52-week high $3.20
Prev. close $0.63 52-week low $0.48
Day low $0.63 Volume 152,700
Day high $0.65 Avg. volume 184,246
50-day MA $0.65 Dividend yield N/A
200-day MA $1.32 Market Cap 21.85M

EQ Stock Price Chart Interactive Chart >

EQ Stock Summary

  • With a market capitalization of $22,369,197, EQUILLIUM INC has a greater market value than only 8.88% of US stocks.
  • Revenue growth over the past 12 months for EQUILLIUM INC comes in at 56.34%, a number that bests 88.97% of the US stocks we're tracking.
  • In terms of volatility of its share price, EQ is more volatile than 92.96% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EQUILLIUM INC are BCDA, AGLE, MOLN, UTSI, and LYRA.
  • EQ's SEC filings can be seen here. And to visit EQUILLIUM INC's official web site, go to equilliumbio.com.

EQ Valuation Summary

  • In comparison to the median Healthcare stock, EQ's price/sales ratio is 82.35% lower, now standing at 0.9.
  • EQ's price/sales ratio has moved NA NA over the prior 56 months.

Below are key valuation metrics over time for EQ.

Stock Date P/S P/B P/E EV/EBIT
EQ 2023-05-23 0.9 0.8 -0.8 -0.2
EQ 2023-05-22 0.9 0.8 -0.8 -0.2
EQ 2023-05-19 0.9 0.7 -0.7 -0.2
EQ 2023-05-18 0.8 0.7 -0.7 -0.2
EQ 2023-05-17 0.8 0.7 -0.7 -0.2
EQ 2023-05-16 0.8 0.7 -0.7 -0.2

EQ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EQ has a Quality Grade of D, ranking ahead of 13.26% of graded US stocks.
  • EQ's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows EQ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -0.645
2021-03-31 0 NA -0.606
2020-12-31 0 NA -0.660
2020-09-30 0 NA -0.693
2020-06-30 0 NA -0.718
2020-03-31 0 NA -0.692

EQ Price Target

For more insight on analysts targets of EQ, see our EQ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.3 (Strong Buy)

Equillium, Inc. (EQ) Company Bio


Equillium Inc. is leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is based in La Jolla, California.


EQ Latest News Stream


Event/Time News Detail
Loading, please wait...

EQ Latest Social Stream


Loading social stream, please wait...

View Full EQ Social Stream

Latest EQ News From Around the Web

Below are the latest news stories about EQUILLIUM INC that investors may wish to consider to help them evaluate EQ as an investment opportunity.

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

LA JOLLA, Calif., June 01, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.

Yahoo | June 1, 2023

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

LA JOLLA, Calif., May 15, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a poster was presented over the weekend at IMMUNOLOGY2023, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, M

Yahoo | May 15, 2023

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2023

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

LA JOLLA, Calif., May 11, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2023 and provided corporate and clinical development updates.

Yahoo | May 11, 2023

News Flash: Analysts Just Made A Meaningful Upgrade To Their Equillium, Inc. (NASDAQ:EQ) Forecasts

Celebrations may be in order for Equillium, Inc. ( NASDAQ:EQ ) shareholders, with the analysts delivering a significant...

Yahoo | May 3, 2023

Read More 'EQ' Stories Here

EQ Price Returns

1-mo 20.75%
3-mo -20.99%
6-mo -57.04%
1-year -74.35%
3-year -78.38%
5-year N/A
YTD -39.62%
2022 -71.88%
2021 -29.53%
2020 58.28%
2019 -58.58%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!